Evaluation the Anti-Cancer Effect of PEGylated Nano-Niosomal Gingerol, on Breast Cancer Cell lines (T47D), In-Vitro

Conclusion: The results showed that IC50 of the formulation of PEGylated nanoniosomal Gingerol is less than the standard drug. It seems, the cause of this phenomenon is due to the effect of Polyethylene glycol, in more stability and slower drug release, in the formulation of PEGylated niosome. Also, Polyethylene glycol makes increase in the drug dealing and its greater influence with the target cell. In this study, more than 76% of the Gingerol drug in PEGylated nanoniosomal formulation were enclose. Also, we could reduce the amount of drug release, as much as possible. PMID: 29580033 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research